← All indications
Gastrointestinal Stromal Tumors
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).
Drugs by status
Approved for this indication (4)
Phase 4 trials (4)
Phase 2 trials (52)
- 68ga-neobomb1
- axitinib
- anlotinib
- avelumab
- sorafenib
- rogaratinib
- Amcasertib
- biib021
- binimetinib
- brostallicin
- temsirolimus
- selinexor
- dovitinib
- encorafenib
- vismodegib
- oblimersen sodium
- paclitaxel
- trametinib
- guadecitabine
- lapatinib
- Luminespib
- epacadostat
- nivolumab
- pembrolizumab
- lenvatinib
- octreotide
- pazopanib
- perifosine
- pexidartinib
- plx9486
- +22 more
Phase 1 trials (26)
- 7-hydroxystaurosporine
- irinotecan
- doxorubicin
- fluorouracil
- ribociclib
- leucovorin
- pimitespib
- telomerase: 540-548 peptide vaccine
- 68ga-nota-rm26
- evofosfamide
- tno155
- amino acids
- midazolam
- mvf-her-2(597-626)
- mvf-her-2 (266-296)
- erlotinib
- isa-720
- sargramostim
- lutetium dotatate lu-177
- alvocidib
- dnx-2440
- ds-6157a
- 4-aminopyridine
- ilixadencel
- ziftomenib
- nn3201
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (37)
- AB Science
- AstraZeneca
- MedImmune
- Bayer
- Blueprint Medicines Corporation
- Deciphera Pharmaceuticals LLC
- Hengrui Therapeutics, Inc.
- Infinity Pharmaceuticals, Inc.
- Central European Cooperative Oncology Group
- National Cancer Institute (NCI)
- Canadian Cancer Trials Group
- Centre Leon Berard
- Harvard University
- Eastern Cooperative Oncology Group
- Grupo Espanol de Investigacion en Sarcomas
- Istituto Nazionale per lo Studio e la Cura dei Tumori
- Italian Sarcoma Group
- Lund University
- Sarcoma Alliance for Research through Collaboration
- Southwest Oncology Group
- UNICANCER
- University of Milan
- University of Valencia
- Australasian Gastro-Intestinal Trials Group
- Scandinavian Sarcoma Group
- University of Ulsan
- Amneal Pharmaceuticals
- Hanmi Pharmaceutical
- University of Lille
- Institut Gustave Roussy
- +7 more
Organization Involved with Phase 2 Indications (81)
- Boston Biomedical
- Daiichi Sankyo
- Takeda
- Amgen
- Schering-Plough
- Merck
- Eli Lilly
- Exelixis
- Genentech
- Plexxikon
- AEterna Zentaris
- Biogen
- Ariad Pharmaceuticals
- Arog Pharmaceuticals, Inc.
- Array BioPharma
- GlaxoSmithKline
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Synta Pharmaceuticals Corp.
- Zai Lab Pty. Ltd.
- Universität Duisburg-Essen
- University of Pittsburgh
- Tzu Chi University
- Chang Gung University
- Cornell University
- Temple University
- Gottfried Wilhelm Leibniz Universität Hannover
- Harbin Medical University
- Institut Bergonié
- Katholieke Universiteit Leuven
- Medical University Innsbruck
- +51 more
Organization Involved with Phase 1 Indications (15)
- Ascentage Pharma Group Inc.
- Dong-A Pharmaceutical
- Immunicum AB
- Threshold Pharmaceuticals
- Chong Kun Dang Pharmaceutical
- TG Therapeutics, Inc.
- Central South University
- Indiana University
- Ludwig Institute for Cancer Research
- University of Iowa
- University of Virginia
- Vanderbilt University
- Calithera Biosciences
- J. W. Goethe University
- Washington University in St. Louis
Organization Involved with Other Experimental Indications (5)